Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
Primary result · Percent change in body weight from baselineResult — go to the resultEstimated difference −10.4 percentage points 95% CI −11.2 to −9.5Authors' conclusion
Once-weekly cagrilintide-semaglutide (at a dose of 2.4 mg each) resulted in a significantly lower body weight than placebo in adults with obesity and type 2 diabetes.
Study context
- Population
- Adults with BMI ≥27, HbA1c 7 to 10%, and T2Drandomized 3:1
- Participants
- 1,206 adults
- Comparison
- Once-weekly cagrilintide-semaglutide (2.4 mg each) vs placebo, with lifestyle intervention, for 68 weeks
- Cagrilintide-semaglutiden = 904
- Placebon = 302reference
- Primary endpoint
- Two primary end points: percent change in body weight and percentage of patients with weight reduction ≥5%
- Follow-up
- Week 68
Methodological detailsphase 3a, double-blind, placebo-controlled, 12 countries, randomized 3:1
- Phase 3a
- Double-blind
- Placebo-controlled
- 12 countries
- Randomized 3:1
Primary result
Percent change in body weight from baseline
Estimated difference
−10.4 percentage points
95% CI −11.2 to −9.5
P < 0.001
Change by group
Cagrilintide-semaglutide
−13.7
estimated mean · %
Placebo
−3.4
estimated mean · %
Cagrilintide-semaglutidevs Placebo
estimated difference −10.4 percentage points (95% CI −11.2 to −9.5); P < 0.001
As reported in the abstract
Further findings
HbA1c ≤6.5%
- Weight reduction ≥10%, ≥15% and ≥20% · more patients with cagrilintide-semaglutide
- P < 0.001 for the last comparison
Weight reduction ≥10%, ≥15% and ≥20%
- More patients with cagrilintide-semaglutide than placebo had reductions of ≥10%, ≥15% and ≥20%
Safety
Gastrointestinal adverse events · most transient and mild or moderate in severity
Original publication
Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. Published 22 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →